LoginRegister

    Glenmark gets USFDA approval for Rythmol SR generic

    Written by Ruby Khatun Khatun   |  

    New Delhi: Glenmark Pharmaceuticals has received final approval from the US health regulator for the generic version of Rythmol SR capsules, an anti-arrhythmic medication, which treats illnesses associated with rapid heart beats.


    "Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (US FDA) for Propafenone Hydrochloride extended-release capsules USP, 225 mg, 325 mg, and 425 mg," Glenmark Pharmaceuticals said in a BSE filing.


    Propafenone Hydrochloride extended-release capsules are generic version of GlaxoSmithKline, LLC's Rythmol Capsules.


    According to IMS Health sales data for the 12 months to July 2017, Rythmol SR capsules achieved annual sales of approximately USD 69.2 million, Glenmark said.


    The company's current portfolio consists of 123 products authorized for distribution in the US marketplace and 63 Abbreviated New Drug Applications (ANDA) pending approval with the USFDA.

    abbreviated new drug applicationsanti-arrhythmicapprovalgenericGlaxoSmithKlineGlenmarkGlenmark PharmaGlenmark Pharmaceuticalsheart beatsPropafenone Hydrochloride extended-release capsulesRythmol CapsulesRythmol SRUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X